The Global Health Body Raises Alert Over Acute Scarcity of Weight-Loss Injections

Fewer than one in 10 people who could benefit from weight-loss injections including Wegovy are able to get them, warns the World Health Organization as it publishes its initial recommendations on the medications.

With more than one billion people worldwide now classified as obese, it is calling for more widespread and fairer access to GLP-1 medication.

Based on forecasts, over two billion are projected to be obese by 2030 unless action is taken.

"Our new guidance acknowledges that excess weight is a chronic disease that can be managed with thorough and continuous care," remarked the agency's head Tedros Adhanom Ghebreyesus.

High costs, insufficient output, and supply-chain constraints are key barriers to universal availability to the treatments that can help people shift significant weight, notes the body.

Skinny Jab Supply Crisis

Even under the present most favorable case, the supply of GLP-1 therapies would only suffice for approximately 100 million people – under 10% of eligible patients, per the health organization.

The guideline urges governments and firms to expand access, through measures like patent sharing.

Exclusive production rights on semaglutide – the core ingredient of a leading brand – is set to lapse in a number of nations in 2026.

How Weight-Loss Jabs Work

GLP-1 drugs replicate a natural hormone to delay gastric emptying, reduce hunger and increase satiety so users eat less.

Patients typically start to lose weight after several weeks of beginning the regular doses.

Evidence indicates people may regain a significant portion within a year of halting the treatment, when their typical appetite return.

To be above a healthy weight elevates your likelihood for contracting medical conditions, such as diabetes, cardiovascular issues, brain attack, and specific cancers.

Obesity concerns individuals in all nations and was associated with 3.7 million fatalities worldwide in 2024, as per the WHO.